

**EXHIBIT B**  
**A MARKED UP VERSION OF THE**  
**CLAIMS AMENDED IN THE INSTANT AMENDMENT**  
**FILED September 5, 2002**  
**IN U.S. PATENT APPLICATION SERIAL NO. 09/161,122**  
**ATTORNEY DOCKET NO. 7682-045-999**

---

2. (amended) An isolated infectious Respiratory Syncytial Virus (RSV) [RSV] particle containing an RSV RNA-comprising a binding site specific for an RNA-directed RNA polymerase operatively linked to an RSV RNA comprising sequences [which comprises a chimeric RSV antigenome or genome] encoding antigenic polypeptides of both RSV-A and RSV-B.

13. (amended) A vaccine comprising a chimeric Respiratory Syncytial Virus (RSV) [RSV] the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of an RSV and a pharmaceutically acceptable carrier.

18. (amended) The vaccine of Claim 13 in which the mRNA coding sequence encodes G and F genes of both Respiratory Syncytial Virus (RSV) A and Respiratory Syncytial Virus B